RxDoctor Payments Data

Chad Coleman, MD

Family Medicine · Midlothian, TXNPI 1194768358

Payments from drug & device makers

$1,300in general payments, 2019–2025

Across 65 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$250
  • Fisher & Paykel Healthcare Inc$239
  • Pfizer$106
  • AstraZeneca$94
  • Lilly USA, LLC$93
  • AbbVie$73
  • plus $444 from 19 others

What the payments were for

  • Food & beverage$1,300100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,300 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$65,440
Medicare patients
124
Services billed
1,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$120,515
EliquisApixaban71$67,803
MounjaroTirzepatide55$64,659
JardianceEmpagliflozin58$44,413
FarxigaDapagliflozin Propanediol49$32,947
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,049
MyrbetriqMirabegron30$26,072
TrulicityDulaglutide21$18,698
XareltoRivaroxaban26$14,818
Repatha SureclickEvolocumab16$11,543
RybelsusSemaglutide11$10,158
GemtesaVibegron14$7,105
Dexlansoprazole DrDexlansoprazole20$6,551
ShingrixVaricella-Zoster Ge/As01b/Pf28$5,902
TrintellixVortioxetine Hydrobromide12$5,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$250$130,673127 claims
Lilly USA, LLCMounjaro, Trulicity$93$83,35676 claims
PfizerEliquis, Paxlovid$106$69,23284 claims
GSKTrelegy Ellipta, Shingrix$33$35,95167 claims
AstraZenecaFarxiga$94$32,94749 claims
Astellas Pharma US IncMyrbetriq$21$26,07230 claims
Johnson & JohnsonXarelto$25$14,81826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Midlothian

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →